Robert James Wills Purchases 3,086 Shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Stock

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Robert James Wills purchased 3,086 shares of Oncternal Therapeutics stock in a transaction on Monday, April 8th. The stock was bought at an average cost of $8.96 per share, with a total value of $27,650.56. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $89,600. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Robert James Wills also recently made the following trade(s):

• On Thursday, March 28th, Robert James Wills bought 6,914 shares of Oncternal Therapeutics stock. The shares were acquired at an average price of $8.48 per share, for a total transaction of $58,630.72.

Oncternal Therapeutics Price Performance

ONCT opened at $8.94 on Friday. Oncternal Therapeutics, Inc. has a fifty-two week low of $5.42 and a fifty-two week high of $13.14. The company has a market cap of $24.05 million, a price-to-earnings ratio of -0.66 and a beta of 1.26. The firm has a 50 day simple moving average of $8.97 and a 200 day simple moving average of $8.02.

Oncternal Therapeutics (NASDAQ:ONCT) last issued its earnings results on Thursday, March 7th. The company reported ($3.11) EPS for the quarter, missing the consensus estimate of ($3.09) by ($0.02). Oncternal Therapeutics had a negative net margin of 5,029.17% and a negative return on equity of 95.87%. The firm had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.17 million. During the same period in the previous year, the company posted ($4.00) EPS. As a group, analysts expect that Oncternal Therapeutics, Inc. will post -12.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on ONCT. StockNews.com upgraded shares of Oncternal Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, March 8th. HC Wainwright boosted their price target on shares of Oncternal Therapeutics to $30.00 and gave the stock a “buy” rating in a research note on Monday, January 29th.

Institutional Investors Weigh In On Oncternal Therapeutics

Large investors have recently bought and sold shares of the company. Mirabella Financial Services LLP bought a new stake in Oncternal Therapeutics in the first quarter valued at approximately $38,000. Prudential Financial Inc. acquired a new position in shares of Oncternal Therapeutics in the second quarter valued at approximately $32,000. Virtu Financial LLC acquired a new position in shares of Oncternal Therapeutics in the second quarter valued at approximately $48,000. Citadel Advisors LLC acquired a new position in shares of Oncternal Therapeutics in the fourth quarter valued at approximately $29,000. Finally, Susquehanna International Group LLP acquired a new position in shares of Oncternal Therapeutics in the first quarter valued at approximately $99,000. Institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.